quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:01:00·22d
PRRelease
Janux Therapeutics Inc. logo

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

JANX· Janux Therapeutics Inc.
Health Care
Original source

Companies

  • JANX
    Janux Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 20UpdateBarclays$14.00
  • Apr 15UpdateUBS$15.00
  • Nov 18UpdateWolfe Research-
  • Sep 17UpdateBarclays$47.00
  • Sep 10UpdateStifel$45.00
  • Sep 10UpdateTruist$100.00

Related

  • ANALYST3d
    Janux Therapeutics downgraded by Barclays with a new price target
  • PR7d
    Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
  • ANALYST8d
    Janux Therapeutics downgraded by UBS with a new price target
  • SEC56d
    SEC Form S-8 filed by Janux Therapeutics Inc.
  • SEC56d
    SEC Form 10-K filed by Janux Therapeutics Inc.
  • SEC56d
    Janux Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR56d
    Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
  • SEC65d
    Amendment: SEC Form SCHEDULE 13G/A filed by Janux Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022